|
|
Transgene - Price Analysis Snapshot
This Report features up to a ten-year record of the equity Price history for Transgene. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.
Transgene. The Group's principal activity is to discover and develop therapeutic vaccines. The Group develops gene-based vaccines used in treatment of cancer and infectious diseases. The Group follows three different strategies. The Group develops vaccines and partners with pharmaceutical companies for further development. The Group also independently develops and commercializes vaccines for certain special markets. The third strategy is to license vector technologies to companies with proprietary genes for short and medium term revenues. The Group markets the products under the brand names MYoDys, TG 4010, TG 4001, TG 1042 and TG 4040. The Group operates mainly in France.
Not the Report you are looking for? Click here for more browsing options.
Layout and Content of a Typical Report
|
|
|
|
|